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Letter to the Editor 
 
Correspondence arising: Modafinil for cognitive neuroenhancement in health non-sleep-deprived-
subjects 
 
 
The review by Battleday and Brem presents an important update on the effects of modafinil in 
healthy, non-sleep-deprived individuals while raising crucial methodological concerns about the 
primary literature being reviewed. However, the review itself has several methodological 
shortcomings and, in our opinion, fails to comply with the standard systematic review methodology. 
Relevant articles, e.g. one by Smith et al. (2004), that could have been detected with the applied 
search terms (modafinil and cognitive), are left out, whereas a study (Ghahremani et al., 2011) that is 
cited in the review and fulfills the inclusion criteria, is not included in the systematic review. By using 
solely the two mentioned search terms, the probability of detecting all relevant articles is very 
limited, and thus, other relevant literature was not included. Further research with a pre-tested, 
more elaborated search strategy provides several additional relevant articles that should have been 
reviewed (Stoops et al., 2005; Dodds et al., 2009; Joo et al., 2008; Schmaal et al., 2013). Two of these 
studies (Smith et al., 2004; Stoops et al., 2005) have already been considered in a previously 
published systematic review on the same topic (Repantis et al., 2010). Since this review is cited in the 
article, the authors could have been aware of their existence.  
Furthermore, the authors report on the effects of modafinil on mood and provide a percentage of 
studies assessing mood. Without having defined mood as an outcome of interest for their review and 
without having specifically searched for trials assessing mood it seems inadequate to comment on 
this topic because, again, a significant number of articles has been left out. A preliminary literature 
search reveals at least nine more articles that provide data on effects of modafinil on the mood of 
healthy individuals. (Warot et al., 1993; Hou et al., 2005; Hou et al., 2007; Samuels et al., 2006; 
Samuels et al., 2007; Taneja et al., 2007; Volkow et al., 2009) Among these are two studies that were 
published before 1990 and not taken into account due to an arbitrary time span set by the authors 
for literature search (Saletu et al., 1989a; 1989b). The same criticism applies to their report on side 
effects. Finally, the claim that the use of modafinil for neuroenhancement purposes is “extensive” is 
not being adequately supported. In fact, it is probably not possible to support such a general 
statement, neither with European nor with U.S. prevalence studies (Maier et al. 2015 – Table 1).  
 
The – mostly null – results that are omitted should be taken into account before stating that 
modafinil is a “well-validated” nootropic agent. By the same token, methodological limitations, which 
are reported here to some extent, put the review’s conclusions into perspective. We argue that not 
only should the ethical issues regarding the use of modafinil for neuroenhancement purposes be a 
matter of discussion, but that more importantly the question of efficacy and safety of modafinil use 
by healthy individuals remains unanswered. In fact, the latter question might even be the rate-
limiting step in the ethical discussion (Forlini et al., 2013). Therefore, we welcome the 
recommendations for future studies that the article provides and hope that future research will 
adequately address this question. 
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